| Literature DB >> 20044048 |
Sandra S Renteria1, Courtney C Clemens, Maria A Croyle.
Abstract
A nasal adenovirus-based vaccine is under development. To determine if aggregation occurs during vaccination, infectious titer (limiting dilution) and capsid integrity (dynamic light scattering) were assessed after extrusion of a model vector from two intranasal delivery devices. Preparations of 2.5x10(12) and 1.25x10(11) virus particles (vp)/ml were studied. Virus aggregated ( approximately 10%) in the multi-dose vessel. Virus titer dropped by one log. Virus in the unit-dose device aggregated ( approximately 1%). Titer remained unchanged. Aggregation was concentration dependent. Formulations prevented aggregation during actuation, freeze-thaw and long-term storage. The device, formulation and dose may significantly influence aggregation and potency of any nasal adenovirus 5-based vaccine. Copyright 2009 Elsevier Ltd. All rights reserved.Entities:
Mesh:
Substances:
Year: 2009 PMID: 20044048 DOI: 10.1016/j.vaccine.2009.12.025
Source DB: PubMed Journal: Vaccine ISSN: 0264-410X Impact factor: 3.641